The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Elkedonia will develop first-in-class Elk1 inhibitors for treatment-resistant depression, targeting neuroplasticity without psychedelic side effects.

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 ...

The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry ...

The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

Most of the company’s new additions, if not already online, will be scheduled for commissioning, validation, or qualification ...

Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers ...

The company describes the compact system as ergonomically designed, providing precision dosing and production floor ...

ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.

ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with the current standard of care, according to a phase III trial.